alexa Causes Of Death In Patients With HIV/AIDS And The Problems Of Antiviral Therapy
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Conference on HIV/AIDS, STDs, & STIs
October 27-29, 2014 Embassy Suites Las Vegas, USA

A G Rakhmanova, S Y Romanova and A A Yakovlev
Accepted Abstracts: J AIDS Clin Res
DOI: 10.4172/2155-6113.S1.009
In Russia 780,000 HIV-infected people registered and 130,000 people died. In St. Petersburg, recorded 50,000 cases from 1987 to 2011 and 8,500 people died. The main causes of death are generalized tuberculosis, rarely other opportunistic diseases and chronic viral hepatitis (CVH) - cirrhosis. Every year in Russia revealed 60-65,000 ?new cases? of HIV-infection and in St. Petersburg 2500 - 3000 per year. In St. Petersburg based on cumulative data from 2006, CVH with cirrhosis diagnosed in 200,000 patients, including patients with HIV infection. CVH patients with HIV infection have a rapidly progressive course disease development with a greater risk of liver failure, cirrhosis and hepatocellular carcinoma (HCC). Materials and Methods: In infectious hospital department, within the last 5 years the causes of death in patients with HIV were studied. Annually about 4500-5000 hospitalized patients with HIV were irregularly receiving ART or have been discontinued it. At the hospital, annually 180 to 250 patients mostly aged 30-40 years were died. Outcomes of antiviral therapy in patients with CVH (genotype 1b) without HIV infection were studied; the SVR rate was 60% on early treatment with Ribavirin and Pegintroferonami with 1-2 fibrosis and at any degree of viral load and the fourth level of fibrosis - 40%. For such patientsa standard therapy with HCV protease inhibitors was prescribed. Results: In 2008-2012, about 1200 patients with HIV/CVH co-infection and level of CD4 350 cells/ul were treated. SVR in patients with genotype 1 b was 70%, but in 20% patients with 3-4 degree of fibrosis relapses were observed, 10% patients did not respond to therapy. Hence, the early antiviral triple therapy (Pegasys + Ribavirin + protease inhibitors) is recommended for all HIV patients with fibrosis at 2-4 stages and even CD4 levels below 200 cells/ul. In St. Petersburg among of 50,000 HIVinfected people, 13,000 patients received ART. Dates of ART administration was delayed due to late diagnosis or late visit to a doctor - more than 50% of patients are starting ART with CD4 levels below 200 cells/ul. Conclusion: Comorbidity in patients with HIV/AIDS and CVH co-infection with an active replication at any degree of fibrosis and at any level of CD4 lymphocytes is a prerequisite for the successful administration of combined antiviral therapy.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version